血栓烷A2--新型抗缺血性脑卒中药物治疗靶点

摘要

Thromboxane A2 (TXA2), a product in arachidonic acid (AA) metabolism, is synthesized by thromboxane synthetase from prostaglandin endoperoxides. TXA2 elicits strong effects in platelet aggregation and vascular smooth muscle contraction, further plays a role in thrombus formation and vascular tense reg-ulation. Based on these biological effects, TXA2 is involved in the pathology of cerebral ischemic stroke, and studies have proved the benefits of TXA2-targeting agents in the prevention and treatment of cerebral vascular disease. This review is to investigate the mechanism in which TXA2 affects cerebral ischemic stroke, and then to introduce and summarize TXA2-targeting agents that protect against cerebral ischemia.%血栓烷A2（TXA2）是血小板聚集和释放的强诱导剂，促进血栓形成；TXA2也可以引起动脉血管收缩，调节血管张力。近年来，越来越多的研究证实了TXA2诱导缺血性脑卒中发生和促进其进展的作用。这提示，TXA2可成为新型抗缺血性脑卒中药物治疗靶点。本文主要探讨了TXA2参与缺血性脑卒中发生与发展的机制，并对以TXA2为靶点防治缺血性脑卒中的药物进行综述。